BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37228058)

  • 1. Fecal Calprotectin in Gastrointestinal Disease.
    Murray J; Kok KB; Ayling RM
    Clin Chem; 2023 Jul; 69(7):699-710. PubMed ID: 37228058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fecal Calprotectin in Inflammatory Bowel Disease].
    Lee J
    Korean J Gastroenterol; 2016 May; 67(5):233-7. PubMed ID: 27206433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of fecal calprotectin.
    Ricciuto A; Griffiths AM
    Crit Rev Clin Lab Sci; 2019 Aug; 56(5):307-320. PubMed ID: 31088326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children.
    Sidler MA; Leach ST; Day AS
    Inflamm Bowel Dis; 2008 Mar; 14(3):359-66. PubMed ID: 18050298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease.
    Konikoff MR; Denson LA
    Inflamm Bowel Dis; 2006 Jun; 12(6):524-34. PubMed ID: 16775498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal Calprotectin.
    Ayling RM; Kok K
    Adv Clin Chem; 2018; 87():161-190. PubMed ID: 30342711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faecal calprotectin -- a useful tool in the management of inflammatory bowel disease.
    Burri E; Beglinger C
    Swiss Med Wkly; 2012; 142():w13557. PubMed ID: 22481443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
    Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
    J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin.
    Sipponen T
    Dig Dis; 2013; 31(3-4):336-44. PubMed ID: 24246984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Fecal Calprotectin Methods for Predicting Relapse of Pediatric Inflammatory Bowel Disease.
    Kittanakom S; Shajib MS; Garvie K; Turner J; Brooks D; Odeh S; Issenman R; Chetty VT; Macri J; Khan WI
    Can J Gastroenterol Hepatol; 2017; 2017():1450970. PubMed ID: 28491862
    [No Abstract]   [Full Text] [Related]  

  • 11. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children.
    Yang Z; Clark N; Park KT
    Clin Gastroenterol Hepatol; 2014 Feb; 12(2):253-62.e2. PubMed ID: 23883663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calprotectin in inflammatory bowel disease.
    Khaki-Khatibi F; Qujeq D; Kashifard M; Moein S; Maniati M; Vaghari-Tabari M
    Clin Chim Acta; 2020 Nov; 510():556-565. PubMed ID: 32818491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pomegranate juice to reduce fecal calprotectin levels in inflammatory bowel disease patients with a high risk of clinical relapse: Study protocol for a randomized controlled trial.
    Scaioli E; Belluzzi A; Ricciardiello L; Del Rio D; Rotondo E; Mena P; Derlindati E; Danesi F
    Trials; 2019 Jun; 20(1):327. PubMed ID: 31171016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin?
    Di Ruscio M; Vernia F; Ciccone A; Frieri G; Latella G
    Inflamm Bowel Dis; 2017 Dec; 24(1):78-92. PubMed ID: 29272479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases.
    Dulai PS; Peyrin-Biroulet L; Danese S; Sands BE; Dignass A; Turner D; Mantzaris G; Schölmerich J; Mary JY; Reinisch W; Sandborn WJ
    Gastroenterology; 2019 Oct; 157(4):1032-1043.e1. PubMed ID: 31228441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fecal calprotectin as a diagnostic marker of inflammatory bowel disease].
    Kostrzewska P; Całkosiński A; Majewski M; Malinowski K
    Pol Merkur Lekarski; 2022 Feb; 50(295):58-61. PubMed ID: 35278302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calprotectin or Lactoferrin: Do They Help.
    Wright EK
    Dig Dis; 2016; 34(1-2):98-104. PubMed ID: 26982329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease.
    Bunn SK; Bisset WM; Main MJ; Gray ES; Olson S; Golden BE
    J Pediatr Gastroenterol Nutr; 2001 Jul; 33(1):14-22. PubMed ID: 11479402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome.
    Otten CM; Kok L; Witteman BJ; Baumgarten R; Kampman E; Moons KG; de Wit NJ
    Clin Chem Lab Med; 2008; 46(9):1275-80. PubMed ID: 18597588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.